Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Hee Jun Choi


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


H.J. Choi, S.W. Kim, J.M. Ryu, S.J. Nam, J. Yu, S.K. Lee, J.E. Lee

Author affiliations

  • Department Of Surgery, Sungkyunkwan University School of Medicine, Samsung Changwon Hospital, 51353 - Changwon/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2445


To evaluate the clinicopathological factors and the oncology outcomes of invasive lobular carcinoma (ILC) patients compared with those of invasive ductal carcinoma (IDC) patients.


This study was a medical record review based on a prospectively-collected database. We surveyed the clinicopathological characteristics and oncology survival between IDC and ILC following curative surgery at ooo Medical Center between March 2007 and February 2015.


The median follow-up time was 60.5 months (range: 3-121 months). There were 352 breast cancer patients with ILC and 7795 breast cancer patients with IDC. There were 13 breast cancer patients with ILC and 1150 breast cancer patients with IDC in the TNBC patients. The IDC patients had 77.7% of cytokeratin (CK) 5/6 and 86.3% of Epidermal growth factor receptor (EGFR), while ILC patients only had 15.4% of CK5/6 and 23.1% of EGFR. In TNBC, patients with ILC showed a tendency to have a worse prognosis than patients with IDC. However, there was no statistical difference in disease-free survival (DFS, p = 0.122) or overall survival (OS, p = 0.093) between TNBC patients with IDC and with ILC.


Patients with ILC have no different oncologic outcome than patients with IDC. However, patients with ILC in TNBC show a tendency to have a worse prognosis than patients with IDC in TNBC. This result may be related to CK5/6 and EGFR. Further research is needed with larger sample sizes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.